In the past years we have developed and characterized TRI-001, a pro-angiogenic Mreg subtype, manufactured in compliance with GMP, which will be employed in a multicenter trial to treat patients suffering from peripheral arterial occlusive disease (PAOD; clinical trial number: EudraCT 2024-517765-16). The gene discussed is MREG; the disease is Peripheral arterial stenosis.